Design and synthesis of conformationally-constrained MMP inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 16, 1998, Pages 2077-2080

  Natchus, Michael G ^b   Cheng, Menyan ^b   Wahl, Christopher T ^b   Pikul, Stanislaw ^b   Almstead, Neil G ^b   Bradley, Rimma S ^b   Taiwo, Yetunde O ^b   Mieling, Glen E ^b   Michelle Dunaway, C ^b   Snider, Catherine E ^a   McIver, John M ^a   Barnett, Bobby L ^b   McPhail, Sara J ^a   Anastasio, Melanie B ^b   De, Biswanath ^b  

^a PROCTER AND GAMBLE COMPANY   (United States)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPROLACTAM; MATRIX METALLOPROTEINASE INHIBITOR;

ARTICLE; DRUG CONFORMATION; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; INHIBITION KINETICS; STRUCTURE ACTIVITY RELATION;

CAPROLACTAM; COLLAGENASES; DRUG DESIGN; INDICATORS AND REAGENTS; KINETICS; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; METALLOENDOPEPTIDASES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PROTEASE INHIBITORS; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; SUCCINATES;

EID: 0032544149     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00370-9     Document Type: Article

References (21)

1. 1. Birkedal-Hansen, H.; Moore, W.G. I.; Bodden, M.K.; Windsor, L.J.; Birkedal-Hansen, B.; DeCarlo, A.; Engler, J.A. Crit. Rev. Oral. Biol. Med. 1993, 4, 197.
2. 2. Matrisian, L.M. Trends Genet. 1990, 6, 212-125.
3. 3. Murphy, G.; Docherty, A.J.P. Am. J. Respir. Cell Mol. Biol. 1992, 7, 120.
4. 4. Docherty, A.J.P.; Murphy, G. Ann. Rheum. Dis. 1990, 49, 469.
5. 5. Woessner, J. F. Jr. FASEB 1991, 5, 2145.
6. 6. Beckett, R.P., Davidson, A.H., Drummond, A.H., Huxley, P., Whittaker, M. Drug Discovery Today 1996, 1, 16.
7. 7. Okada, Y., Shinmei, M., Tanaka, O., Naka, K., Kimura, A., Nakanishi, I., Bayliss, M.T., Iwata, K., Nagase, H. Lab. Invest. 1992, 66, 680.
8. 8. Walakovits, L.A., Moore, V.L., Bharadwaj, N., Gallick, G.S., Lark, M.W. Arthritis Rheum. 1992, 35, 35.
9. 9. Cawston, T.E. Pharmacol. Ther. 1996, 70, 163.
10. 10. Bramhall, S. R. Int. J. Pancreatology 1997, 21, 1.
11. 11. Chambers, A. F., Matrisian, L. M. J. Natl Cancer Inst. 1997, 89, 1260.
12. 12. Aitken, L.W., Sodek, S., MvCulloch CAG, J. J. Periodont. Res. 1995, 30, 23.
13. 13. Beckett, R. P., Whittaker, M. Exp. Opin. Ther. Patents 1998, 8, 259.
14. 14. Johnson, W. H., Roberts, N. A., Borkakoti, N. J. Enzyme Inhibition 1987, 2, 1.
15. 15. Evans, D. A., Ennis, M. D., and Mathre, D. J. J. Am. Chem. Soc. 1982,104, 1737.
16. 16. Evans, D. A. Asymmetric Synthesis; Academic Press: Orlando, FL, 1984; Vol. 3, pp 1-110.
17. 17. Beckett, R. P., Crimmin, M. J., Davis, M. H., Spavold, Z Synlett 1993, 137.
18. 3[H]-reduced, carboxymethylated transferrin (Okada, Y.; Nagase, H.; Harris, E. D. J. Biol. Chem. 1986, 261, 14245).
19. 19. Collagenase inhibition assay, MMP-1 activity was monitored using a fluorescence assay previously described (Knight, C. G.; Willenbrock, F.; Murphy, G. FEBS Lett. 1992, 296, 263).
20. 20. Several examples have been documented by X-ray crystallography where the blocking Arg-214 group present in MMP-1 can be displaced by the inhibitor to form a larger S1′ subsite. Babine, R. E. Bender, S. L. Chem. Rev. 1997, 97, 1359.
21. 21. The atomic coordinates of compound 22 bound to truncated stomelysin have been deposited to the Protein Data Bank, and the file name is pdb1biw.ent.